GlassScriptPhysician profile
Daniel Anthony Ochs
NPI 1588135651
$10,304.57
in general payments reported to CMS, 2019-2025
28 companies · $1,514 in 2025
The $1,514 reported for 2025 was more than what 95% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $84.65 · 2020: $212 · 2021: $656 · 2022: $6,207 · 2023: $585 · 2024: $1,047 · 2025: $1,514.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,128 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,127.56 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $6,293.03 | 2020-2025 | Cequa |
| Biotissue Holdings INC. | $709.43 | 2020-2025 | |
| Bausch & Lomb Americas INC. | $464.33 | 2023-2025 | Miebo, Xiidra, Vyzulta |
| Alcon Vision LLC | $409.81 | 2022-2025 | Tryptyr, Clareon, Eysuvis |
| Dompe US, INC. | $301.80 | 2024-2025 | Oxervate |
| Johnson & Johnson Surgical Vision, INC. | $271.67 | 2022-2025 | Tecnis Iol, Tecnis Simplicity |
| Lkc Technologies, INC. | $227.56 | 2023-2024 | |
| Kala Pharmaceuticals, INC. | $209.21 | 2021-2022 | |
| Amgen INC. | $207.60 | 2024-2025 | Tepezza |
| Tarsus Pharmaceuticals, INC. | $206.56 | 2024-2025 | Xdemvy |
| Coopervision INC. | $158.01 | 2022-2025 | Myday Contact Lens, Biofinity Contact Lens |
| Allergan, INC. | $143.15 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $111.47 | 2019-2025 | Eylea, Eylea Hd |
| Novartis Pharmaceuticals Corporation | $108.40 | 2021-2023 | |
| Johnson & Johnson Vision Care, INC. | $80.81 | 2021-2025 | Acuvue |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb, A Division of Bausch Health US, LLC | $62.01 | 2020-2021 | |
| Optovue, INC. | $59.52 | 2019 | |
| Sight Sciences, INC. | $53.43 | 2022-2023 | Omni Surgical System |
| Genentech USA, INC. | $38.15 | 2024-2025 | Vabysmo |
| Astellas Pharma US INC | $33.63 | 2023 | |
| Omeros Corporation | $32.12 | 2021 | |
| Aerie Pharmaceuticals, INC. | $24.23 | 2021 | |
| Harrow Eye, LLC | $23.80 | 2024 | |
| Glaukos Corporation | $23.76 | 2024 | Istent Trabecular Micro-Bypass System Model Is3 |
| Eyevance Pharmaceuticals LLC | $18.85 | 2022 | |
| Oyster Point Pharma, INC. | $16.56 | 2022 | |
| Stryker Corporation | $11.57 | 2019 | |
| Tearlab Corp | $4.10 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Ochs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.